Structure Therapeutics Inc. American Depositary Shares Cash Flow Conversion Efficiency
Structure Therapeutics Inc. American Depositary Shares cash flow conversion efficiency. Based on the latest financial reports, Structure Therapeutics Inc. American Depositary Shares (GPCR) has a cash flow conversion efficiency ratio of -0.089x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-120.11 Million) by net assets ($1.35 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Structure Therapeutics Inc. American Depositary Shares (2020–2025)
Cash flow conversion efficiency of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025. This chart illustrates how Structure Therapeutics Inc. American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View GPCR stock price and chart for real-time trading data and today's change.
Structure Therapeutics Inc. American Depositary Shares Cash Flow Conversion Ratio Explained
Structure Therapeutics Inc. American Depositary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Structure Therapeutics Inc. American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Structure Therapeutics Inc. American Depositary Shares ranked by their cash flow conversion efficiency. Also see GPCR company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gujarat Mineral Development Corporation Limited
NSE:GMDCLTD
|
0.036x |
|
Investment and Industrial Development Joint Stock Corp
VN:BCM
|
-0.049x |
|
Punjab & Sind Bank
NSE:PSB
|
-0.574x |
|
Siloam International Hospitals
JK:SILO
|
0.027x |
|
Sky Gold Limited
NSE:SKYGOLD
|
-0.084x |
|
Guangdong Ellington Electronics Technology Co Ltd
SHG:603328
|
0.053x |
|
Hammond Power Solutions Inc
TO:HPS-A
|
-0.021x |
|
Shenzhen Vital New Material Co. Ltd.
SHE:301319
|
N/A |
Annual Cash Flow Conversion Efficiency for Structure Therapeutics Inc. American Depositary Shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025. Review GPCR free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.52 Billion | $-222.20 Million | -0.147x | -8.65% |
| 2024-12-31 | $864.84 Million | $-116.64 Million | -0.135x | +23.15% |
| 2023-12-31 | $452.97 Million | $-79.49 Million | -0.175x | -143.81% |
| 2022-12-31 | $-115.14 Million | $-46.12 Million | 0.401x | -19.37% |
| 2021-12-31 | $-64.73 Million | $-32.16 Million | 0.497x | -21.85% |
| 2020-12-31 | $-22.47 Million | $-14.28 Million | 0.636x | -- |
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more